Genzyme targets biosurgery in deal worth up to $900 million
This article was originally published in Clinica
Genzyme is to accelerate its efforts in biosurgery through the formation of a new company. It plans to merge two of its divisions and to buy Biomatrix, which it will then incorporate into the single unit to form separately-traded Genzyme Biosurgery. The new company will focus on the high-growth areas of bio-orthopaedics and cardiothoracic surgery.